Citizen Petition from SafeVetMeds, Inc.
Details
The document's own metadata, straight from the source system.
- Title
- Citizen Petition from SafeVetMeds, Inc.
- Posted
- Aug 11, 2025
- Comment period
- Aug 11, 2025 – ?
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jun 29, 2026Comment from Emma ASupportIndividual
A pet owner is submitting a comment in support of the petition to stop the use of Zorbium. They argue that the drug caused severe adverse reactions in their cat, including extreme hyperactivity and insomnia, and believe the risks of the medication far outweigh its benefits.
Read comment → - Jun 28, 2026Comment from Bonnie RaeSupportIndividual
The commenter is a pet owner who shares a personal account of their cat's severe injury and death following the administration of Zorbium by a veterinarian. They argue that Zorbium should never have been approved and should be removed from the market immediately.
Read comment → - Jun 27, 2026Comment from Margaret ColonSupportIndividualRead comment →
- Jun 27, 2026Comment from Margaret ColonSupportIndividualRead comment →
- Jun 24, 2026Comment from AnonymousSupportIndividual
The commenter, a pet owner whose cat died after being administered Zorbium, urges the FDA to withdraw the drug from the market due to its high potency, lack of owner disclosure, and documented fatalities. They argue that the drug poses a serious risk to cats and humans and request that, at minimum, the manufacturer be required to add "DEATHS" as a known adverse event in the labeling.
Read comment → - Jun 24, 2026Comment from Melissa KistlerSupportIndividual
A pet owner is reporting a severe adverse reaction in their cat following the off-label administration of Zorbium transdermal solution. The commenter provides specific details about the dosage, the symptoms experienced (including opioid toxicity), and the manufacturer's response to support the petition.
Read comment →
